Antisense inhibition of cyclin D1 expression is equivalent to flavopiridol for radiosensitization of zebrafish embryos

International Journal of Radiation Oncology Biology Physics

Volumn 66, Issue 2, 2006, Pages 546-551

  McAleer, Mary Frances ^a   Duffy, Kevin T ^a   Davidson, William R ^a   Kari, Gabor ^a   Dicker, Adam P ^a,b   Rodeck, Ulrich ^a,b   Wickstrom, Eric ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cyclin D; Flavopiridol; Hydroxyprolyl phosphono peptide nucleic acids; Ionizing radiation; Radiosensitizer

Indexed keywords

CELLS; GENES; IONIZING RADIATION; NUCLEIC ACIDS; OLIGOMERS; TISSUE; TOXICITY;

CYCLIN D; FLAVOPIRIDOL; HYDROXYPROLYL-PHOSPHONO PEPTIDE NUCLEIC ACIDS; RADIOSENSITIZER;

ENZYME INHIBITION;

ANTISENSE HYDROXYLPROLYLPHOSPHONONUCLEIC ACID OLIGOMER; COMPLEMENTARY DNA; CYCLIN D1; FLAVOPIRIDOL; OLIGOMER; RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EMBRYO; EMBRYO DEVELOPMENT; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; IONIZING RADIATION; MORTALITY; NONHUMAN; PHENOTYPE; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION RESPONSE; RADIOSENSITIZATION; SIGNAL TRANSDUCTION; VERTEBRATE; ZEBRA FISH;

ANIMALS; CYCLIN D1; DOSE-RESPONSE RELATIONSHIP, RADIATION; EMBRYO, NONMAMMALIAN; FLAVONOIDS; MODELS, ANIMAL; OLIGODEOXYRIBONUCLEOTIDES; PHENOTYPE; PIPERIDINES; RADIATION-SENSITIZING AGENTS; SURVIVAL ANALYSIS; ZEBRAFISH;

EID: 33748288207     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.05.040     Document Type: Article

References (23)

1. de Azevedo Jr. W.F., Mueller-Dieckmann H.-J., Schulze-Gahmen U., et al. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci USA 93 (1996) 2735-2740
2. Raju U., Nakata E., Mason K.A., et al. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells. Cancer Res 63 (2003) 3263-3267
3. Mason K.A., Hunter N.R., Raju U., et al. Flavopiridol increases therapeutic ratio of radiotherapy by preferentially enhancing tumor radioresponse. Int J Radiat Oncol Biol Phys 59 (2004) 1181-1189
4. Newcomb E.W. Flavopiridol: Pleiotropic biological effects enhance its anti-cancer activity. Anticancer Drugs 15 (2004) 411-419
5. Blagosklonny M.V. Flavopiridol, an inhibitor of transcription: Implications, problems and solutions. Cell Cycle 3 (2004) 1537-1542
6. Duffy K.T., McAleer M.F., Davidson W.R., et al. Coordinate control of cell cycle regulatory genes in zebrafish development tested by cyclin D1 knockdown with morpholino phosphorodiamidates and hydroxyprolyl-phosphono peptide nucleic acids. Nucleic Acids Res 33 (2005) 4914-4921
7. Hall E.J. Radiation, the two-edged sword: Cancer risks at high and low doses. Cancer J 6 (2000) 343-350
8. Westerfield M. The zebrafish book. A guide for the laboratory use of zebrafish (Danio rerio). 4th ed (2000), University of Oregon Press, Eugene, OR
9. Kimmel C.B., Ballard W.W., Kimmel S.R., et al. Stages of embryonic development of the zebrafish. Development Dynamics 203 (1995) 253-310
10. McAleer M.F., Davidson C., Davidson W.R., et al. Novel use of zebrafish as a vertebrate model to screen radiation protectors and sensitizers. Int J Radiat Oncol Biol Phys 61 (2005) 10-13
11. Sato S., Kajiyama Y., Sugano M., et al. Flavopiridol as a radio-sensitizer for esophageal cancer cell lines. Dis Esophagus 17 (2004) 338-344
12. Camphausen K., Brady K.J., Burgan W.E., et al. Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of gammaH2AX foci. Mol Cancer Ther 3 (2004) 409-416
13. Jung C., Motwani M., Kortmansky J., et al. The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells. Clin Cancer Res 9 (2003) 6052-6061
14. Byrd J.C., Shinn C., Waselenko J.K., et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 92 (1998) 3804-3816
15. Drees M., Dengler W.A., Roth T., et al. Flavopiridol (L86-8275): Selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin Cancer Res 3 (1997) 273-279
16. Senderowicz A.M. Flavopiridol: The first cyclin-dependent kinase inhibitor in human clinical trials. Invest New Drugs 17 (1999) 313-320
17. Stadler W.M., Vogelzang N.J., Amato R., et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago Phase II Consortium study. J Clin Oncol 18 (2000) 371-375
18. Tan A.R., Yang X., Berman A., et al. Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. Clin Cancer Res 10 (2004) 5038-5047
19. Bible K.C., Lensing J.L., Nelson S.A., et al. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin Cancer Res 11 (2005) 5935-5941
20. Thisse B., Pflumio S., Fürthauer M., et al. Expression of the zebrafish genome during embryogenesis. ZFIN Direct Data Submission (2001)
21. 99mTc-peptide-peptide nucleic acid-peptide chimeras. J Nucl Med 45 (2004) 2070-2082
22. Bonham M.A., Brown S., Boyd A.L., et al. An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers. Nucleic Acids Res 23 (1995) 1197-1203
23. 99mTc-peptide-peptide nucleic acid probes for imaging oncogene mRNAs in tumours. Nucl Med Commun 24 (2003) 857-863